Literature DB >> 16410717

Detection of BRAF gene mutation in primary choroidal melanoma tissue.

Grazia Malaponte1, Massimo Libra, Pietro Gangemi, Valentina Bevelacqua, Katia Mangano, Fabio D'Amico, Maria C Mazzarino, Franca Stivala, James A McCubrey, Salvatore Travali.   

Abstract

Numerous BRAF mutations have been detected in melanoma biopsy specimens and cell lines. In contrast, several studies report lack of BRAF mutations in uveal melanoma including primary and metastatic choroidal and ciliary body melanomas. To our knowledge, for the first time, here we report a case of choroidal melanoma harboring the BRAF mutation (V600E). The activation of RAF/MEK/ERK pathway, although independent of BRAF mutation, was reported in uveal melanoma. The presence of V600E mutation indicates that the RAF/MEK/ERK pathway, in addition to cutaneous melanoma progression, may play a role in the choroidal melanoma development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410717     DOI: 10.4161/cbt.5.2.2429

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  11 in total

Review 1.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

2.  Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.

Authors:  Grazia Ambrosini; Christine A Pratilas; Li-Xuan Qin; Madhavi Tadi; Oliver Surriga; Richard D Carvajal; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2012-05-01       Impact factor: 12.531

Review 3.  Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Authors:  Vivian Chua; Dominic Lapadula; Clinita Randolph; Jeffrey L Benovic; Philip B Wedegaertner; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2017-02-21       Impact factor: 5.852

Review 4.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 5.  Emerging insights into the molecular pathogenesis of uveal melanoma.

Authors:  Solange Landreville; Olga A Agapova; J William Harbour
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

6.  Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Authors:  Alan L Ho; Elgilda Musi; Grazia Ambrosini; Jayasree S Nair; Shyamprasad Deraje Vasudeva; Elisa de Stanchina; Gary K Schwartz
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

7.  Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).

Authors:  Richard D Carvajal; Gary K Schwartz; Helen Mann; Ian Smith; Paul D Nathan
Journal:  BMC Cancer       Date:  2015-06-10       Impact factor: 4.430

8.  Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2.

Authors:  Dongsheng Yan; Xiang Da Dong; Xiaoyan Chen; Shasha Yao; Lihua Wang; Jiao Wang; Chao Wang; Dan-Ning Hu; Jia Qu; LiLi Tu
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  The T1799A point mutation is present in posterior uveal melanoma.

Authors:  C S Janssen; R Sibbett; F L Henriquez; I C McKay; E G Kemp; F Roberts
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

Review 10.  The genetics of uveal melanoma: current insights.

Authors:  Hildur Helgadottir; Veronica Höiom
Journal:  Appl Clin Genet       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.